[1] |
Boehncke WH, Schon MP. Psoriasis[J]. Lancet, 2015, 386(9997):983⁃994. DOI: 10.1016/S0140⁃6736(14)61909⁃7.
|
[2] |
Zanvit P, Konkel JE, Jiao X, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis[J]. Nat Commun, 2015, 6: 8424. DOI: 10.1038/ncomms9424.
|
[3] |
Baurecht H, Hotze M, Brand S, et al. Genome⁃wide comparative analysis of atopic dermatitis and psoriasis gives insight into opposing genetic mechanisms[J]. Am J Hum Genet, 2015, 96(1): 104⁃120. DOI: 10.1016/j.ajhg.2014.12.004.
|
[4] |
Quaranta M, Knapp B, Garzorz N, et al. Intraindividual genome analysis reveals a specific molecular signature of psoriasis and eczema[J]. Science Translational Medicine, 2014, 6(244). DOI: ARTN 244ra9010.1126/scitranslmed.3008946.
|
[5] |
Stuart PE, Nair RP, Tsoi LC, et al. Genome⁃wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture[J]. Am J Hum Genet, 2015, 97(6): 816⁃836. DOI: 10.1016/j.ajhg.2015.10.019.
|
[6] |
Yan S, Xu Z, Lou F, et al. NF⁃kappa B⁃induced microRNA⁃31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis[J]. Nat Commun, 2015, 6: 7652. DOI: Artn 765210.1038/Ncomms8652.
|
[7] |
Man XY, Chen XB, Li W, et al. Analysis of epithelial⁃mesenchymal transition markers in psoriatic epidermal keratinocytes[J]. Open Biol, 2015, 5(8). DOI: Artn 15003210.1098/Rsob.150032.
|
[8] |
Hara⁃Chikuma M, Satooka H, Watanabe S, et al. Aquaporin⁃3⁃mediated hydrogen peroxide transport is required for NF⁃kappa B signalling in keratinocytes and development of psoriasis[J]. Nat Commun, 2015, 6: 7454. DOI: Artn 745410.1038/Ncomms8454.
|
[9] |
Rizvi S, Chaudhari K, Syed BA. The psoriasis drugs market[J]. Nat Rev Drug Dis, 2015, 14(11): 745⁃746. DOI: 10.1038/nrd4763.
|
[10] |
Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate⁃to⁃severe chronic plaque psoriasis: a phase 3 randomised non⁃inferiority trial[J]. Lancet, 2015, 386(9993): 552⁃561. DOI: 10.1016/S0140⁃6736(14)62113⁃9.
|
[11] |
Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis[J]. N Eng J Med, 2015, 373(14): 1318⁃1328. DOI: 10.1056/Nejmoa1503824.
|
[12] |
Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin⁃17A in patients with psoriatic arthritis[J]. N Eng J Med, 2015, 373(14): 1329⁃1339. DOI: 10.1056/Nejmoa1412679.
|
[13] |
Gordon KB, Duffin KC, Bissonnette R, et al. A phase 2 trial of guselkumab versus adalimumab for plaque psoriasis[J]. N Eng J Med, 2015, 373(2): 136⁃144. DOI: 10.1056/Nejmoa1501646.
|
[14] |
Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin⁃23[J]. Nature, 2015, 521(7551): 222⁃226. DOI: 10.1038/nature14175.
|
[15] |
Bachelez H. Interleukin⁃17 inhibition: a route to psoriasis clearance?[J]. Lancet, 2015, 386(9993): 510⁃512. DOI: 10.1016/S0140⁃6736(15)60857⁃1.
|
[16] |
Schukur L, Geering B, Charpin⁃El Hamri G, et al. Implantable synthetic cytokine converter cells with AND⁃gate logic treat experimental psoriasis[J]. Sci Tran Med, 2015, 7(318): 318ra201. DOI: ARTN 318ra20110.1126/scitranslmed.aac4964.
|
[17] |
Benedek T. Psoriasis and its specific vaccine therapy[J]. Acta Derm Venereol Suppl (Stockh), 1955, 35(Suppl 33): 1⁃20.
|
[18] |
Benedek T. Specific vaccine therapy of psoriasis vulgaris, based on its etiology and pathogenesis[J]. Dermatol Wochenschr, 1955, 131(17): 414⁃419.
|
[19] |
Fry L, Baker BS, Powles AV. Psoriasis ⁃ a possible candidate for vaccination[J]. Clin Dev Immunol, 2006, 13(2⁃4): 361⁃367. DOI: 10.1080/17402520600800861.
|
[20] |
Baker BS, Owles AV, Fry L. A possible role for vaccination in the treatment of psoriasis?[J]. G Ital Dermatol Venereol, 2008, 143(2): 105⁃117.
|